In de cruciale studie BR.21 in NSCLC, was de incidentie van ILD (0,8%) hetzelfde in zowel de placebo als in de Tarceva groepen. ###>In the pivotal study BR.21 in NSCLC, the incidence of ILD (0.8%) was the same in both the placebo and Tarceva groups.